Glenmark Pharmaceutical, a manufacturer of generic formulation products and API, gained on Wednesday after its USA a subsidiary, Glenmark Generics Inc. has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Eszopiclone Tablets. Glenmark will commence distribution of the product immediately.

Eszopiclone Tablets are Glenmark's generic version of Sunovion's Lunesta. Eszopiclone is indicated for the treatment of insomnia. The approval is for the 1mg, 2mg and 3mg tablets.

Shares of the company are trading at Rs 586, up Rs 4.65, or 0.80% at the Bombay Stock Exchange (BSE) on Wednesday at 12:07 p.m.

The scrip has touched an intra-day high of Rs 587 and low of Rs 582.50. The total volume of shares traded at the BSE is 8,887.

In the earlier session, the shares climbed 1.23%, or Rs 7.05, at Rs 581.35. Currently, the stock is trading down 4.25% from its 52-week high of Rs 612 and above 25.35% over the 52-week low of Rs 467.50.